Biofrontera Valuation

Is B8FK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of B8FK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate B8FK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate B8FK's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for B8FK?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for B8FK. This is calculated by dividing B8FK's market cap by their current preferred multiple.
What is B8FK's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	€17.38m

B8FK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.7x
Enterprise Value/EBITDA	-6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does B8FK's PS Ratio compare to its peers?

The above table shows the PS ratio for B8FK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	14.7x
SBX SynBiotic	8.3x	39.7%	€31.9m
HIGH Cantourage Group	35.4x	36.2%	€58.9m
0RX Redx Pharma	13.3x	-37.6%	€65.0m
APPH Apontis Pharma	2x	17.8%	€81.0m
B8FK Biofrontera	0.8x	n/a	€17.4m

Price-To-Sales vs Peers: B8FK is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (14.7x).

Price to Earnings Ratio vs Industry

How does B8FK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.9%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: B8FK is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Pharmaceuticals industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is B8FK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

B8FK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate B8FK's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.